For the Inventor, By the Inventor

Enter inventor name

Montreuil, France

Dominique Lesuisse

USPTO Granted Patents = 24 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 1)

Average Co-Inventor Count = 2.7

ph-index = 7

Forward Citations = 128(Granted Patents)

Location History:

Paris, FR (1991 - 2004)
Montreuil, FR (2005 - 2010)

Company Filing History:

Aventis Pharma S.a.

Hoechst Marion Roussel

Roussel Uclaf, Department Des Brevets

Years Active: 1991-2010

Loading Chart...

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7825115 - Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors (2010-11-02),

2. 7786114 - Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors (2010-08-31),

3. 7759379 - Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors (2010-07-20),

4. 7629374 - Use of aminoindazole derivatives for the inhibition of tau phosphorylation (2009-12-08),

5. 7582669 - Aminoindazole derivatives as medicaments and pharmaceutical compositions including them (2009-09-01),

6. 7407981 - Aminoindazole derivatives as medicaments and pharmaceutical compositions including them (2008-08-05),

7. 7354933 - Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors (2008-04-08),

8. 7196109 - Aminoindazole derivatives as medicaments and pharmaceutical compositions including them (2007-03-27),

9. 7166629 - Aminoindazole derivatives as medicaments and pharmaceutical compositions including them (2007-01-23),

10. 7019011 - Aminoindazole derivatives as medicaments and pharmaceutical compositions including them (2006-03-28),

11. 6949579 - Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof (2005-09-27),

12. 6794415 - Biphenyl compounds and their use as oestrogenic agents (2004-09-21),

13. 6563008 - Biphenyl compounds and their use as oestrogenic agents (2003-05-13),

14. 6448294 - Biphenyl compounds and their use as oestrogenic agents (2002-09-10),

15. 6365775 - Biphenyl compounds and their use as oestrogenic agents (2002-04-02),

Title: Dominique Lesuisse: Pioneering Innovator in Sustainable Pharmaceuticals

Introduction:

Dominique Lesuisse, a visionary inventor based in Montreuil, France, is renowned for his passion for innovation and dedication to creating a more sustainable future. With a remarkable portfolio of 24 patents, Dominique Lesuisse continues to inspire the next generation of inventors and innovators worldwide.

Latest Patents:

Among his latest patents, Dominique Lesuisse has made significant contributions to the pharmaceutical industry. His inventions include cyclic urea compounds, which have shown promise as kinase inhibitors for the treatment of physiological disorders such as solid tumors. Additionally, his work on bis-azaindole derivatives highlights his expertise in developing novel compounds for protein kinase inhibition.

Career Highlights:

Dominique Lesuisse has accumulated a wealth of experience through his tenure at prominent pharmaceutical companies such as Aventis Pharma S.A. and Roussel Uclaf. His innovative spirit and commitment to excellence have driven him to push the boundaries of scientific discovery in the field of pharmaceuticals.

Collaborations:

Throughout his career, Dominique Lesuisse has collaborated with esteemed professionals in the industry, including his coworkers Gilles Dutruc-Rosset and Thomas Rooney. These collaborations have not only enhanced his own creativity and expertise but have also resulted in groundbreaking advancements in pharmaceutical research and development.

Conclusion:

In conclusion, Dominique Lesuisse stands as a true pioneer in the realm of sustainable pharmaceuticals, with a steadfast commitment to driving innovation and creating a positive impact on global healthcare. His remarkable achievements and collaborative efforts underscore his lasting legacy as an inventor dedicated to shaping a better future for generations to come.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…